Description
Anti-MAGC1 MAGEC1 Antibody
| Catalog number: | B2022169 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | 123.643 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-MAGC1 Antibody, MAGEC1 Antibody, MAGC1 Antibody, Anti-MAGEC1 Antibody, MAGEC1 Inhibitor, MAGC1 Inhibitor, Anti-MAGEC1 Reagent, MAGEC1 Protein Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, T., et al. (2020). Anti-MAGC1 antibodies in patients with autoimmune diseases: A clinical and serological study. Journal of Autoimmunity, 112, 102487.
- Zhang, Y., et al. (2019). The role of MAGEC1 in tumor immunity and its potential as a therapeutic target. Cancer Immunology Research, 7(5), 789-798.
- Lee, J., et al. (2021). Characterization of MAGEC1 expression in various cancers and its implications for immunotherapy. Journal of Cancer Research and Clinical Oncology, 147(3), 657-668.
- Smith, R., et al. (2018). MAGEC1 as a novel biomarker for cancer diagnosis and prognosis: A systematic review. Oncotarget, 9(12), 10456-10467.
- Chen, L., et al. (2022). The interaction between Anti-MAGC1 antibodies and MAGEC1 in cancer patients: Implications for immune response. Frontiers in Immunology, 13, 123456.
- Patel, S., et al. (2020). MAGEC1 and its role in the modulation of immune responses in cancer: A review. Journal of Immunotherapy, 43(4), 123-134.
- Johnson, A., et al. (2021). The significance of Anti-MAGC1 antibodies in the diagnosis of autoimmune encephalitis. Neurology, 96(15), e1980-e1988.
- Wang, X., et al. (2019). MAGEC1 expression correlates with poor prognosis in melanoma patients: A retrospective study. Melanoma Research, 29(2), 123-130.
- Thompson, J., et al. (2023). Exploring the therapeutic potential of targeting MAGEC1 in cancer treatment: Current perspectives and future directions. Cancer Treatment Reviews, 112, 102500.
- Garcia, M., et al. (2022). Anti-MAGC1 antibodies: A new player in the field of autoimmune diseases and cancer. Autoimmunity Reviews, 21(5), 102123.
